Literature DB >> 10399161

The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting.

S W Wong1, A M Rangan, A M Bilous, J Boyages, V Gebski, E M Benson.   

Abstract

This study aimed to determine the prognostic significance of DNA ploidy and S-phase fraction (SPF) measurements in our laboratory for patients with node-negative breast cancer. Frozen tumors from axillary node-negative breast cancer patients (n = 50) treated at Westmead Hospital, NSW, between 1988 and 1991 were analysed by flow cytometry. The median duration of follow-up for all patients was 8.4 years. Forty-six specimens provided evaluable DNA histograms with 43% (n = 20) diploid and 56% (n = 26) aneuploid tumors identified. Comparisons of DNA ploidy status and SPF were made with traditional prognostic variables, which included age, menopausal status, tumor size, histologic grade and hormone receptor status. Our results showed that there was no significant difference in disease-free or overall survival between patients with diploid and aneuploid tumors. Histologic grade 3 tumors were more likely to be aneuploid and had higher SPF than grade 1 or 2 tumors. Patients with grade 3 tumors and a high SPF were four times more likely to relapse than the rest of the population. These results indicate that DNA flow cytometric analysis in our laboratory provides additional prognostic data that could be utilised alongside traditional clinical and histopathologic indicators for predicting outcome for patients.

Entities:  

Mesh:

Year:  1999        PMID: 10399161     DOI: 10.1080/003130299105241

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

1.  DNA ploidy analyses in 218 consecutive Pakistani breast cancer patients: does it add anything?

Authors:  E Khan; Z Mapara; S Khan; N Arshad; T Siddiqui; S Pervez
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

3.  Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases.

Authors:  Lik Hang Lee; Hua Yang; Gilbert Bigras
Journal:  Sci Rep       Date:  2014-05-30       Impact factor: 4.379

4.  Expression of DNA topoisomerase II-α: Clinical significance in laryngeal carcinoma.

Authors:  Yan Feng; Haili Zhang; Wei Gao; Shuxin Wen; Hui Huangfu; Ruifang Sun; Wei Bai; Binquan Wang
Journal:  Oncol Lett       Date:  2014-07-22       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.